Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the cardiovascular safety profile of new antidiabetic therapies. We assessed cardiovascular outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo in patients with type 2 diabetes who had had a recent acute coronary syndrome. METHODS: We randomly assigned patients with type 2 diabetes and either an acute myocardial infarction or unstable angina requiring hospitalization within the previous 15 to 90 days to receive alogliptin or placebo in addition to existing antihyperglycemic and cardiovascular drug therapy. The study design was a double-blind, noninferiority trial with a prespecified noninferiority margin of 1.3 for the hazard ratio for the primary end point of a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. RESULTS: A total of 5380 patients underwent randomization and were followed for up to 40 months (median, 18 months). A primary end-point event occurred in 305 patients assigned to alogliptin (11.3%) and in 316 patients assigned to placebo (11.8%) (hazard ratio, 0.96; upper boundary of the one-sided repeated confidence interval, 1.16; P<0.001 for noninferiority). Glycated hemoglobin levels were significantly lower with alogliptin than with placebo (mean difference, -0.36 percentage points; P<0.001). Incidences of hypoglycemia, cancer, pancreatitis, and initiation of dialysis were similar with alogliptin and placebo. CONCLUSIONS: Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo. (Funded by Takeda Development Center Americas; EXAMINE ClinicalTrials.gov number, NCT00968708.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DPP-4 inhibitors do not have significant GI adverse effects and may be used in early combination with metformin.1038–1043”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1038]
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [20]
In the citing paper
“Pharmaceutical interventions of 1.5 to 3 years duration report HbA1c reductions of 0.2 to 1.0% with DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 agonists (6, 7, 49).”
In the citing paper
“GLP-1 agents, including dipeptidyl peptidase-4 (DPP-4) inhibitor and glucagon-like peptide-1 receptor agonist (GLP-1 Ra), enhance insulin secretion in pancreatic b-cell and showed many benefits in treating diabetes mellitus type 2 but are not a common choice for GDM [117,118].”
From Gestational Diabetes Mellitus—Recent Literature Review (2022) · cites this paper as [117]
In the citing paper
“Evidence that glucose lowering reduces the rates of cardiovascular events and death has not been convincingly shown, 4-6”
From Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (2015) · cites this paper as [5]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Self-citationUniversal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Task Force Members, Thygesen, K., Alpert, J. S., White, H. D., Biomarker Group, Jaffe, A. S., Apple, F. S., Galvani, M., Katus, H. A., Newby, L. K., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm355 · Cited by 2,541
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Cited by
Items 101–200 of 1,012
Margolis, K. L., O’Connor, P. J., Morgan, T. M., Buse, J. B., Cohen, R. M., Cushman, W. C., Cutler, J. A., Evans, G. W., Gerstein, H. C., Grimm, R. H., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2334 · Cited by 259
“context of the ACCORD results, perhaps it is not surprising that such studies have failed to show CVD benefit (20,21).”
BackgroundSelf-citationESVM Guideline on peripheral arterial disease
Frank, U., Nikol, S., Belch, J., Boc, V., Brodmann, M., Carpentier, P. H., Chraim, A., Canning, C., Dimakakos, E., Gottsäter, A., et al. (2019) · Vasa · doi:10.1024/0301-1526/a000834 · Cited by 250
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 258
Pharmacological treatment of hyperglycemia in type 2 diabetes
Taylor, S. I., Yazdi, Z. S., & Beitelshees, A. L. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142243 · Cited by 245
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Nauck, M. A., & Meier, J. J. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0566 · Cited by 254
Udell, J. A., Cavender, M. A., Bhatt, D. L., Chatterjee, S., Farkouh, M. E., & Scirica, B. M. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00044-3 · Cited by 254
Maack, C., Lehrke, M., Backs, J., Heinzel, F. R., Hulot, J.-S., Marx, N., Paulus, W. J., Rossignol, P., Taegtmeyer, H., Bauersachs, J., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy596 · Cited by 246
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults
Lipscombe, L., Booth, G., Butalia, S., Dasgupta, K., Eurich, D. T., Goldenberg, R., Khan, N., MacCallum, L., Shah, B. R., & Simpson, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.034 · Cited by 246
“There was a nonstatistically significant increase in hospitalizations for CHF with alogliptin in the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial (49) and there is limited experience treating people with a history of CHF with linagliptin; therefore, these agents should…”
InfluentialDiabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control
Borghetti, G., von Lewinski, D., Eaton, D. M., Sourij, H., Houser, S. R., & Wallner, M. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01514 · Cited by 238
Li, L., Li, S., Deng, K., Liu, J., Vandvik, P. O., Zhao, P., Zhang, L., Shen, J., Bala, M. M., Sohani, Z. N., et al. (2016) · BMJ · doi:10.1136/bmj.i610 · Cited by 238
Diabetes Mellitus and Heart Failure
Lehrke, M., & Marx, N. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.014 · Cited by 236
Glycemic Goals in Diabetes: Trade-off Between Glycemic Control and Iatrogenic Hypoglycemia
Cryer, P. E. (2014) · Diabetes · doi:10.2337/db14-0059 · Cited by 236
Nolan, C. J., Ruderman, N. B., Kahn, S. E., Pedersen, O., & Prentki, M. (2015) · Diabetes · doi:10.2337/db14-0694 · Cited by 226
“ACCORD (42), Look AHEAD (64), EXAMINE (73), SAVOR-TIMI 53 (72).”
BackgroundSilbert, R., Salcido-Montenegro, A., Rodriguez-Gutierrez, R., Katabi, A., & McCoy, R. G. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1018-0 · Cited by 229
“These trials include EMPA-REG OUTCOME (empagliflozin),[34] CANVAS (canagliflozin),[35] LEADER (liraglutide),[36] SAVOR-TIMI 53 (saxagliptin),[37] TECOS (sitagliptin),[38] EXAMINE (alogliptin),[39] ELIXA (lixisenatide),[40] SUSTAIN-6 (semaglutide),[41] and DEVOTE (insulin degludec).”
InfluentialCardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
Holman, R. R., Sourij, H., & Califf, R. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60794-7 · Cited by 227
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E., Sato, K., Teramoto, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0002 · Cited by 191
Makrilakis, K. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16152720 · Cited by 216
“Rates of pancreatitis, cancer, and hypoglycemia, were also similar between groups [81].”
Result12. Older Adults:Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s012 · Cited by 219
Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions
Shao, S., Xu, Q., Yu, X., Pan, R., & Chen, Y. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107503 · Cited by 221
“Although clinical studies have emphasized cardiovascular safety, no evidences of reduced major adverse cardiovascular events with different DPP4is were observed (Aroor et al., 2018; Green et al., 2015; Scirica et al., 2013; White et al., 2013).”
BackgroundGestational Diabetes Mellitus—Recent Literature Review
Modzelewski, R., Stefanowicz-Rutkowska, M. M., Matuszewski, W., & Bandurska-Stankiewicz, E. M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195736 · Cited by 223
Coronary Artery Disease and Diabetes Mellitus
Aronson, D., & Edelman, E. R. (2014) · Cardiology Clinics · doi:10.1016/j.ccl.2014.04.001 · Cited by 222
A multicenter observational study of incretin-based drugs and heart failure
Filion, K. B., Azoulay, L., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Hu, N., Paterson, J. M., Targownik, L., Turin, T. C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506115 · Cited by 196
Uno, H., Wittes, J., Fu, H., Solomon, S. D., Claggett, B., Tian, L., Cai, T., Pfeffer, M. A., Evans, S. R., & Wei, L.-J. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1741 · Cited by 220
“The event rates are low in most safety studies (9, 11, 13, 14).”
McGuire, D. K., Van de Werf, F., Armstrong, P. W., Standl, E., Koglin, J., Green, J. B., Bethel, M. A., Cornel, J. H., Lopes, R. D., Halvorsen, S., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.0103 · Cited by 217
Comparative review of dipeptidyl peptidase‐4 inhibitors and sulphonylureas
Deacon, C. F., & Lebovitz, H. E. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12610 · Cited by 213
“Recent results from the first three trials with DPP-4 inhibitors confirmed the low incidence of acute pancreatitis; there were, however, small non-statistically significant imbalances in the number of events, being numerically higher with DPP-4 inhibitors than placebo [31,33,74].”
BackgroundResultPersson, F., Nyström, T., Jørgensen, M. E., Carstensen, B., Gulseth, H. L., Thuresson, M., Fenici, P., Nathanson, D., Eriksson, J. W., Norhammar, A., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13077 · Cited by 212
Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212
Marx, N., Rosenstock, J., Kahn, S. E., Zinman, B., Kastelein, J. J., Lachin, J. M., Espeland, M. A., Bluhmki, E., Mattheus, M., Ryckaert, B., et al. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115570301 · Cited by 212
13. Older Adults: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s013 · Cited by 199
The cardiovascular safety of diabetes drugs–insights from the rosiglitazone experience
Hiatt, W. R., Kaul, S., & Smith, R. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1309610 · Cited by 204
van Baar, M. J. B., van Ruiten, C. C., Muskiet, M. H. A., van Bloemendaal, L., IJzerman, R. G., & van Raalte, D. H. (2018) · Diabetes Care · doi:10.2337/dc18-0588 · Cited by 199
Glycemic Variability and Oxidative Stress: A Link between Diabetes and Cardiovascular Disease?
Saisho, Y. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151018381 · Cited by 195
“However, recently two randomized controlled trials failed to show a beneficial effect of DPP-4 inhibitors on CVD outcome [94,95].”
BackgroundBalestrieri, M. L., Rizzo, M. R., Barbieri, M., Paolisso, P., D’Onofrio, N., Giovane, A., Siniscalchi, M., Minicucci, F., Sardu, C., D’Andrea, D., et al. (2015) · Diabetes · doi:10.2337/db14-1149 · Cited by 196
“GLP-1 levels (Active GLP-1 [7-36] Specific ELISA Kit; Epitope Diagnostics) were measured after an overnight fast (at 8:00 A.”
MethodLower extremity arterial disease in patients with diabetes: a contemporary narrative review
Nativel, M., Potier, L., Alexandre, L., Baillet-Blanco, L., Ducasse, E., Velho, G., Marre, M., Roussel, R., Rigalleau, V., & Mohammedi, K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0781-1 · Cited by 194
Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy
Longo, M., Bellastella, G., Maiorino, M. I., Meier, J. J., Esposito, K., & Giugliano, D. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00045 · Cited by 192
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00367-2 · Cited by 193
Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
Bonora, B. M., Avogaro, A., & Fadini, G. P. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s233538 · Cited by 177
“%) at the end of the studies and similar to that achieved in CVOTs with DPP4i 35 – 38 or lixisenatide 39 that failed to show cardiovascular bene fi t.”
Should metformin remain the first-line therapy for treatment of type 2 diabetes?
Baker, C., Retzik-Stahr, C., Singh, V., Plomondon, R., Anderson, V., & Rasouli, N. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820980225 · Cited by 181
Zhong, J., Maiseyeu, A., Davis, S. N., & Rajagopalan, S. (2015) · Circulation Research · doi:10.1161/circresaha.116.305665 · Cited by 189
“In both EXAMINE and SAVOR-TIMI53 trials, the primary outcome composed of cardiovascular death, myocardial infarction, and ischemic stroke was noninferior in DPP4i group when compared with placebo group.(137,138) In both trials the median duration of follow-up was <4 years, the majority of whom were on evidence-based t…”
Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials
Monami, M., Dicembrini, I., & Mannucci, E. (2014) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.01.017 · Cited by 192
“On the other hand, SAVOR-TIMI53 [3] and EXAMINE [2] did not report all severe cases of heart failure, but only those leading to hospitalization, which is an investigator-driven event.”
BackgroundMethodInfluentialDiabetes Mellitus and Heart Failure
Lehrke, M., & Marx, N. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.010 · Cited by 188
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Polyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. A., Katsiki, N., Underwood, P., Park, K.-H., Seufert, J., Kang, E. S., et al. (2018) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 187
Diabetes Mellitus and Cardiovascular Disease: Emerging Therapeutic Approaches
Schmidt, A. M. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.310961 · Cited by 183
JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Tsutsui, H., Ide, T., Ito, H., Kihara, Y., Kinugawa, K., Kinugawa, S., Makaya, M., Murohara, T., Node, K., Saito, Y., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-21-0431 · Cited by 183
Vijan, S., Sussman, J. B., Yudkin, J. S., & Hayward, R. A. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.2894 · Cited by 185
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riddle, M. C., Rydén, L., Xavier, D., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13028 · Cited by 183
Self-citationJapanese Clinical Practice Guideline for Diabetes 2016
Haneda, M., Noda, M., Origasa, H., Noto, H., Yabe, D., Fujita, Y., Goto, A., Kondo, T., & Araki, E. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12810 · Cited by 181
The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?
Muskiet, M. H. A., Smits, M. M., Morsink, L. M., & Diamant, M. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.272 · Cited by 181
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Bansilal, S., Bhatt, D. L., Leiter, L. A., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.01.012 · Cited by 181
Deaminative (Carbonylative) Alkyl‐Heck‐type Reactions Enabled by Photocatalytic C−N Bond Activation
Jiang, X., Zhang, M., Xiong, W., Lu, L., & Xiao, W. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201813689 · Cited by 183
Seferović, P. M., Coats, A. J. S., Ponikowski, P., Filippatos, G., Huelsmann, M., Jhund, P. S., Polovina, M. M., Komajda, M., Seferović, J., Sari, I., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1673 · Cited by 178
“3 1 Notably, the higher incidence of HF hospitalisation has not resulted in excess all-cause or CV mortality in the group treated with either saxagliptin in SAVOR-TIMI 53, or alogliptin in EXAMINE.”
BackgroundInfluentialGlucagon-Like Peptide-1: Glucose Homeostasis and Beyond
Cho, Y. M., Fujita, Y., & Kieffer, T. J. (2014) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170315 · Cited by 174
Buse, J. B., Bain, S. C., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Pratley, R. E., Linder, M., Monk Fries, T., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2251 · Cited by 175
Self-citationSonesson, C., Johansson, P. A., Johnsson, E., & Gause-Nilsson, I. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0356-y · Cited by 176
“Since then, a number of large CV outcome studies to clarify the effects of new classes of glucose-lowering therapies have either been conducted [43–47] or are ongoing [48–50].”
BackgroundHydrolyzed Infant Formula and Early β-Cell Autoimmunity: A Randomized Clinical Trial
Knip, M., Åkerblom, H. K., Becker, D., Dosch, H.-M., Dupre, J., Fraser, W., Howard, N., Ilonen, J., Krischer, J. P., Kordonouri, O., et al. (2014) · JAMA · doi:10.1001/jama.2014.5610 · Cited by 167
Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk
Goldfine, A. B., & Shoelson, S. E. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88884 · Cited by 172
Naito, R., & Miyauchi, K. (2017) · International Heart Journal · doi:10.1536/ihj.17-191 · Cited by 172
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
Lorber, D. (2014) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s61438 · Cited by 168
“safety of saxagliptin and alogliptin, respectively, but failed to show a benefit on CV outcomes in either case.(80,81) Therefore,”
BackgroundRecent advances in pharmacotherapy for hypertriglyceridemia
Sahebkar, A., Chew, G. T., & Watts, G. F. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2014.07.002 · Cited by 164
McMurray, J. J. V., Ponikowski, P., Bolli, G. B., Lukashevich, V., Kozlovski, P., Kothny, W., Lewsey, J. D., & Krum, H. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2017.08.004 · Cited by 165
Marx, N., & McGuire, D. K. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw110 · Cited by 165
McGuire, D. K., Alexander, J. H., Johansen, O. E., Perkovic, V., Rosenstock, J., Cooper, M. E., Wanner, C., Kahn, S. E., Toto, R. D., Zinman, B., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038352 · Cited by 164
F. Piepoli, M. (2017) · International Journal of Behavioral Medicine · doi:10.1007/s12529-016-9583-6 · Cited by 162
Udell, J. A., Bhatt, D. L., Braunwald, E., Cavender, M. A., Mosenzon, O., Steg, P. G., Davidson, J. A., Nicolau, J. C., Corbalan, R., Hirshberg, B., et al. (2015) · Diabetes Care · doi:10.2337/dc14-1850 · Cited by 163
“Details of whether this trend was observed for other CV end points, including hospitalization for heart failure, are yet to be reported (37).”
BackgroundMethodFerdinandy, P., Andreadou, I., Baxter, G. F., Bøtker, H. E., Davidson, S. M., Dobrev, D., Gersh, B. J., Heusch, G., Lecour, S., Ruiz-Meana, M., et al. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000348 · Cited by 159
13. Older Adults: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s013 · Cited by 161
JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Tsutsui, H., Ide, T., Ito, H., Kihara, Y., Kinugawa, K., Kinugawa, S., Makaya, M., Murohara, T., Node, K., Saito, Y., et al. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.04.023 · Cited by 158
Pharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 184
Abd El Aziz, M., Cahyadi, O., Meier, J. J., Schmidt, W. E., & Nauck, M. A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13924 · Cited by 160
“The present study makes use of the largest database of placebo-controlled cardiovascular outcomes studies examining GLP-1 RAs and DPP-4 Is.(6-16) Notably, cases of pancreatitis and pancreatic cancer have been carefully assessed in these trials and were adjudicated by dedicated expert committees.”
BackgroundMethodInfluentialGhosh-Swaby, O. R., Goodman, S. G., Leiter, L. A., Cheng, A., Connelly, K. A., Fitchett, D., Jüni, P., Farkouh, M. E., & Udell, J. A. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30038-3 · Cited by 159
Kusaka, H., Koibuchi, N., Hasegawa, Y., Ogawa, H., & Kim-Mitsuyama, S. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0473-7 · Cited by 155
Glycemic variability in the development of cardiovascular complications in diabetes
Nusca, A., Tuccinardi, D., Albano, M., Cavallaro, C., Ricottini, E., Manfrini, S., Pozzilli, P., & Di Sciascio, G. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3047 · Cited by 158
Seufert, J., & Gallwitz, B. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12251 · Cited by 156
“However, while the cardiovascular safety of both agents has now been proven in large longterm cardiovascular outcome studies, neither agent achieved superiority to placebo for the primary endpoint [113,114].”
BackgroundResultCardiac Autonomic Neuropathy in Diabetes: A Predictor of Cardiometabolic Events
Vinik, A. I., CASELLINI, C. M., Parson, H. K., Colberg, S. R., & Névoret, M.-L. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00591 · Cited by 177
Doubly blind: a systematic review of gender in randomised controlled trials
Phillips, S. P., & Hamberg, K. (2016) · Global Health Action · doi:10.3402/gha.v9.29597 · Cited by 155
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update
Lipscombe, L., Butalia, S., Dasgupta, K., Eurich, D. T., MacCallum, L., Shah, B. R., Simpson, S., & Senior, P. A. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.08.001 · Cited by 153
“No DPP4i has shown inferiority or superiority compared to placebo for the risk of major CV events (20-23).”
BackgroundInsulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease
Lo, C., Toyama, T., Wang, Y., Lin, J., Hirakawa, Y., Jun, M., Cass, A., Hawley, C. M., Pilmore, H., Badve, S. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011798.pub2 · Cited by 100
Benefits and harms of intensive glycemic control in patients with type 2 diabetes
Rodriguez-Gutierrez, R., Gonzalez-Gonzalez, J. G., Zuñiga-Hernandez, J. A., & McCoy, R. G. (2019) · BMJ · doi:10.1136/bmj.l5887 · Cited by 152
The Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications
Avogaro, A., & Fadini, G. P. (2014) · Diabetes Care · doi:10.2337/dc14-0865 · Cited by 164
“So far, randomized controlled trials do not support cardiovascular protective effects of DPP4-I (23,28), but studies with longer follow-”
BackgroundInfluentialMita, T., Katakami, N., Yoshii, H., Onuma, T., Kaneto, H., Osonoi, T., Shiraiwa, T., Kosugi, K., Umayahara, Y., Yamamoto, T., et al. (2016) · Diabetes Care · doi:10.2337/dc15-0781 · Cited by 152
“3% over 2 years, a finding almost identical to that of a recent randomized clinical study with alogliptin (13) and other DPP-4 inhibitors (14,15).”
ResultSitagliptin: A Review in Type 2 Diabetes
Scott, L. J. (2017) · Drugs · doi:10.1007/s40265-016-0686-9 · Cited by 170
“Postmarketing CV safety outcome trials for alogliptin (EXAMINE) [65] and saxagliptin (SAVOR-TIMI 53) [64] also indicated that these respective drugs were noninferior to the placebo arm in terms of the specified MACE primary outcome for each trial.”
BackgroundInfluentialMann, J. F. E., Fonseca, V., Mosenzon, O., Raz, I., Goldman, B., Idorn, T., von Scholten, B. J., Poulter, N. R., & The LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Circulation · doi:10.1161/circulationaha.118.036418 · Cited by 147
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.05.007 · Cited by 145
“In the EXAMINE trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care), alogliptin had no effect on the risk of cardiovascular events compared with placebo in patients with DM and recent acute coronary syndrome.(98) In contrast to SAVOR TIMI-53, no significant difference in the risk of H…”
Postprandial Hyperlipidemia and Remnant Lipoproteins
Masuda, D., & Yamashita, S. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv16003 · Cited by 145
Toward a broader view of mechanisms of drug cardiotoxicity
Mamoshina, P., Rodríguez, B., & Bueno‐Orovio, A. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100216 · Cited by 167
Metformin and other antidiabetic agents in renal failure patients
Lalau, J., Arnouts, P., Sharif, A., & Broe, M. E. D. (2014) · Kidney International · doi:10.1038/ki.2014.19 · Cited by 159
Rados, D. V., Pinto, L. C., Remonti, L. R., Leitão, C. B., & Gross, J. L. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001992 · Cited by 143
Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
Saraiva, F. K., & Sposito, A. C. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0142-7 · Cited by 143
“On the other hand, EXAMINE study showed that T2D patients, who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo [28].”
Result2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M. T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0120 · Cited by 178
Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
Abdul-Ghani, M., DeFronzo, R. A., Del Prato, S., Chilton, R., Singh, R., & Ryder, R. E. J. (2017) · Diabetes Care · doi:10.2337/dc16-2736 · Cited by 145
Bell, D. S. H., & Goncalves, E. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13512 · Cited by 139
“The EXAMINE and TIMI 53 studies resulted in similar borderline findings concerning the effect of DPP-4 inhibitors on the incidence of NAF.(77,78) In the randomized, double-blinded, prospective, placebo-controlled EXAMINE study, in which the DPP-4 inhibitor alogliptin was compared to standard of care in patients with T…”
BackgroundResultBatzias, K., Antonopoulos, A. S., Oikonomou, E., Siasos, G., Bletsa, E., Stampouloglou, P. K., Mistakidi, C.-V., Noutsou, M., Katsiki, N., Karopoulos, P., et al. (2018) · Journal of Diabetes Research · doi:10.1155/2018/1232583 · Cited by 140
“Furthermore, dipeptidyl peptidase-4 (DPP-4) inhibitors seem to exert neutral effects on CVD risk as shown for alogliptin in the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial [14] and for sitagliptin in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS…”
BackgroundGlucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis
Cameron-Vendrig, A., Reheman, A., Siraj, M. A., Xu, X. R., Wang, Y., Lei, X., Afroze, T., Shikatani, E., El-Mounayri, O., Noyan, H., et al. (2016) · Diabetes · doi:10.2337/db15-1141 · Cited by 137
García‐Ropero, Á., Badimón, J. J., & Santos‐Gallego, C. G. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1551877 · Cited by 161
“In fact, saxagliptin was associatedwith higher risk of HF [26] and alogliptin [27] showed a trend toward more HF episodes.”
BackgroundResultZinman, B., Inzucchi, S. E., Lachin, J. M., Wanner, C., Fitchett, D., Kohler, S., Mattheus, M., Woerle, H. J., Broedl, U. C., Johansen, O. E., et al. (2017) · Stroke · doi:10.1161/strokeaha.116.015756 · Cited by 136
Mita, T., Katakami, N., Shiraiwa, T., Yoshii, H., Onuma, T., Kuribayashi, N., Osonoi, T., Kaneto, H., Kosugi, K., Umayahara, Y., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2145 · Cited by 136
“Calcium channel blocker 39 (28) 45 (33) 0.”
Sibony, R. W., Segev, O., Dor, S., & Raz, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417147 · Cited by 167
“In the SAVOR trial, saxagliptin increased the risk for HHF. Similar non-significant results were demonstrated in the EXAMINE trial [33], although the reason is currently unknown [32,34].”
ResultAmbulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012
Turner, L. W., Nartey, D., Stafford, R. S., Singh, S., & Alexander, G. C. (2014) · Diabetes Care · doi:10.2337/dc13-2097 · Cited by 136
“There is also an increasingly amount of scientific information available about their association with cardiovascular outcomes (20,21).”
BackgroundSafety of dipeptidyl peptidase 4 inhibitors: a perspective review
Karagiannis, T., Boura, P., & Tsapas, A. (2014) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098614523031 · Cited by 131
Brunton, S. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12361 · Cited by 130
Metadata
- Authors
- White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., Cushman, W. C., & Zannad, F.
- Affiliations
- University of Connecticut (US)
- Brigham and Women's Hospital (US)
- University of Sheffield (GB)
- Cleveland Clinic (US)
- Park Nicollet Health Services (US)
- University of Chicago (US)
- Takeda (United States) (US)
- Harvard University (US)
- Memphis VA Medical Center (US)
- Inserm (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-03
- Volume
- 369
- Issue
- 14
- Pages
- 1327-1335
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2127854619
- Cited by
- 2,502
- References
- 23
- Citations by year
- 2026: 43 · 2025: 60 · 2024: 79 · 2023: 107 · 2022: 124 · 2021: 161 · 2020: 225 · 2019: 243 · 2018: 288 · 2017: 279 · 2016: 329 · 2015: 260 · 2014: 248 · 2013: 44
- FWCI
- 231.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0611-10248)
- National Institutes of Health (UL1TR000041)
- Japan Society for the Promotion of Science (24591075)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- alogliptin, DPP-4 inhibitors, type 2 diabetes, acute coronary syndrome, major adverse cardiovascular events, cardiovascular safety, non-inferiority, HbA1c, acute myocardial infarction, unstable angina, hypoglycemia
- MeSH terms
- Aged, Angina, Unstable, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Piperidines, Uracil, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.